When Luke Miels took charge at pharmaceutical group GSK in January, it seemed like a natural next step.
The 51-year-old Australian had wide industry experience and since 2017 had served as chief commercial officer, becoming a trusted lieutenant to his predecessor, Dame Emma Walmsley.
But while the transition was smooth, he has inherited a demanding agenda. Miels must prove the business can deliver commercially successful new drugs to offset looming patent expiries, hit ambitious growth targets that some in the market doubt are achievable and win over sceptical investors.
您已阅读11%（575字），剩余89%（4815字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。